Metabolic Associated Fatty Liver Disease (MAFLD) Research 2020-2021
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 6541
Interests: NAFLD; NASH; metabolic syndrome; HCC
Special Issues, Collections and Topics in MDPI journals
This Special Issue of IJMS, entitled “Metabolic Associated Fatty Liver Disease (MAFLD) Research 2020-2021”, will include a selection of recent research topics and current review articles in the field of primary and secondary fatty liver syndromes.
The healthy liver is almost devoid of any fat content, and any significant accumulation of intrahepatic fat in humans will invariably signal an impaired metabolic health for which no effective and safe drug treatment is licensed.
MAFLD may be either genetic or strongly associated with the metabolic syndrome (with which it has a bidirectional nexus) and common endocrine derangements. MAFLD has a definite sexual dimorphism which dictates epidemiological features, natural course, and, probably, response to treatment. It does not spare any age group from childhood to elderhood and is an ever-increasing cause of chronic liver disease worldwide. Projections estimate that it will become the most common cause of liver transplantation by 2030.
Not only is the clinical and public health burden of MAFLD determined by liver-related morbidity and mortality (e.g., cirrhosis, liver failure, and hepatocellular carcinoma), but MAFLD is also a potentially extrahepatic and systemic disorder featuring incident cardiometabolic diseases (i.e., type 2 diabetes, chronic kidney disease and major cardiovascular events), extrahepatic tumors, and psoriasis. Moreover, MAFLD often concurs with common environmental injuries such as alcohol, hepatotoxic drugs, and chronic viral infections (e.g., HCV and HIV).
On this background of epidemiological and clinical evidence, additional basic, clinical, and translational research is eagerly awaited in the MAFLD arena in order to fully characterize role of sex/gender, genetic and hormonal modifiers, natural history, molecular pathogenesis of MAFLD, risk of progression to fibrosis, cirrhosis and hepatocarcinoma, and cofactors/ “common threads” determining the development of extrahepatic diseases and management strategies.
Prof. Dr. Amedeo Lonardo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- anticoagulation therapy
- animal models
- arterial hypertension
- atrial fibrillation
- cardiovascular disease and risk
- cell biology
- cell cultures
- clinical trials
- drug treatment
- evidence-based medicine
- gut microbiota
- heart failure
- heart valve
- insulin resistance
- lean NAFLD/NASH
- lifestyle changes
- metabolic syndrome
- molecular biology
- natural history
- nonalcoholic fatty liver disease
- portal hypertension
- personalized medicine
- sex medicine
- system biology
- type 2 diabetes
- thyroid disease
- uric acid